Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18

1.

New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice.

Yang PY, Zou H, Amso Z, Lee C, Huang D, Woods AK, Nguyen-Tran VTB, Schultz PG, Shen W.

Bioconjug Chem. 2020 Apr 3. doi: 10.1021/acs.bioconjchem.0c00093. [Epub ahead of print]

PMID:
32243137
2.

Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.

Liu YA, Jin Q, Zou Y, Ding Q, Yan S, Wang Z, Hao X, Nguyen B, Zhang X, Pan J, Mo T, Jacobsen K, Lam T, Wu TY, Petrassi HM, Bursulaya B, DiDonato M, Gordon WP, Liu B, Baaten J, Hill R, Nguyen-Tran V, Qiu M, Zhang YQ, Kamireddy A, Espinola S, Deaton L, Ha S, Harb G, Jia Y, Li J, Shen W, Schumacher AM, Colman K, Glynne R, Pan S, McNamara P, Laffitte B, Meeusen S, Molteni V, Loren J.

J Med Chem. 2020 Mar 26;63(6):2958-2973. doi: 10.1021/acs.jmedchem.9b01624. Epub 2020 Feb 20.

PMID:
32077280
3.

Engineering a Potent, Long-Acting, and Periphery-Restricted Oxytocin Receptor Agonist with Anorexigenic and Body Weight Reducing Effects.

Pflimlin E, Zhou Z, Amso Z, Fu Q, Lee C, Muppiddi A, Joseph SB, Nguyen-Tran V, Shen W.

J Med Chem. 2020 Jan 9;63(1):382-390. doi: 10.1021/acs.jmedchem.9b01862. Epub 2019 Dec 18.

PMID:
31850759
4.

Neratinib protects pancreatic beta cells in diabetes.

Ardestani A, Li S, Annamalai K, Lupse B, Geravandi S, Dobrowolski A, Yu S, Zhu S, Baguley TD, Surakattula M, Oetjen J, Hauberg-Lotte L, Herranz R, Awal S, Altenhofen D, Nguyen-Tran V, Joseph S, Schultz PG, Chatterjee AK, Rogers N, Tremblay MS, Shen W, Maedler K.

Nat Commun. 2019 Nov 1;10(1):5015. doi: 10.1038/s41467-019-12880-5.

5.

Design of a Long-Acting and Selective MEG-Fatty Acid Stapled Prolactin-Releasing Peptide Analog.

Pflimlin E, Lear S, Lee C, Yu S, Zou H, To A, Joseph S, Nguyen-Tran V, Tremblay MS, Shen W.

ACS Med Chem Lett. 2019 Jul 5;10(8):1166-1172. doi: 10.1021/acsmedchemlett.9b00182. eCollection 2019 Aug 8.

PMID:
31413801
6.

Identification of Potent and Selective RIPK2 Inhibitors for the Treatment of Inflammatory Diseases.

He X, Da Ros S, Nelson J, Zhu X, Jiang T, Okram B, Jiang S, Michellys PY, Iskandar M, Espinola S, Jia Y, Bursulaya B, Kreusch A, Gao MY, Spraggon G, Baaten J, Clemmer L, Meeusen S, Huang D, Hill R, Nguyen-Tran V, Fathman J, Liu B, Tuntland T, Gordon P, Hollenbeck T, Ng K, Shi J, Bordone L, Liu H.

ACS Med Chem Lett. 2017 Sep 27;8(10):1048-1053. doi: 10.1021/acsmedchemlett.7b00258. eCollection 2017 Oct 12.

7.

Rational Design of Dual Agonist-Antibody Fusions as Long-acting Therapeutic Hormones.

Liu Y, Wang Y, Zhang Y, Liu T, Jia H, Zou H, Fu Q, Zhang Y, Lu L, Chao E, Parker H, Nguyen-Tran V, Shen W, Wang D, Schultz PG, Wang F.

ACS Chem Biol. 2016 Nov 18;11(11):2991-2995. Epub 2016 Oct 5.

8.

Rational design of a Kv1.3 channel-blocking antibody as a selective immunosuppressant.

Wang RE, Wang Y, Zhang Y, Gabrelow C, Zhang Y, Chi V, Fu Q, Luo X, Wang D, Joseph S, Johnson K, Chatterjee AK, Wright TM, Nguyen-Tran VT, Teijaro J, Theofilopoulos AN, Schultz PG, Wang F.

Proc Natl Acad Sci U S A. 2016 Oct 11;113(41):11501-11506. Epub 2016 Sep 23.

9.

Multifunctional Antibody Agonists Targeting Glucagon-like Peptide-1, Glucagon, and Glucose-Dependent Insulinotropic Polypeptide Receptors.

Wang Y, Du J, Zou H, Liu Y, Zhang Y, Gonzalez J, Chao E, Lu L, Yang P, Parker H, Nguyen-Tran V, Shen W, Wang D, Schultz PG, Wang F.

Angew Chem Int Ed Engl. 2016 Sep 26;55(40):12475-8. doi: 10.1002/anie.201606321. Epub 2016 Sep 6.

PMID:
27595986
10.

Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.

Shen W, Taylor B, Jin Q, Nguyen-Tran V, Meeusen S, Zhang YQ, Kamireddy A, Swafford A, Powers AF, Walker J, Lamb J, Bursalaya B, DiDonato M, Harb G, Qiu M, Filippi CM, Deaton L, Turk CN, Suarez-Pinzon WL, Liu Y, Hao X, Mo T, Yan S, Li J, Herman AE, Hering BJ, Wu T, Martin Seidel H, McNamara P, Glynne R, Laffitte B.

Nat Commun. 2015 Oct 26;6:8372. doi: 10.1038/ncomms9372.

11.

Risks of complaints and adverse disciplinary findings against international medical graduates in Victoria and Western Australia.

Nguyen ND, Nguyen TV.

Med J Aust. 2013 Mar 18;198(5):256. No abstract available. Erratum in: Med J Aust. 2013 Apr 15;198(7):367. Nguyen, Tran V [corrected to Nguyen, Tuan V].

PMID:
23496391
12.

Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity.

Jacobson LH, Commerford SR, Gerber SP, Chen YA, Dardik B, Chaperon F, Schwartzkopf C, Nguyen-Tran V, Hollenbeck T, McNamara P, He X, Liu H, Seidel HM, Jaton AL, Gromada J, Teixeira S.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Dec;384(6):565-81. doi: 10.1007/s00210-011-0686-y. Epub 2011 Sep 25.

PMID:
21947251
13.

Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.

Epple R, Cow C, Xie Y, Azimioara M, Russo R, Wang X, Wityak J, Karanewsky DS, Tuntland T, Nguyêñ-Trân VT, Cuc Ngo C, Huang D, Saez E, Spalding T, Gerken A, Iskandar M, Seidel HM, Tian SS.

J Med Chem. 2010 Jan 14;53(1):77-105. doi: 10.1021/jm9007399.

PMID:
19928766
14.

PPAR{delta} agonism activates fatty acid oxidation via PGC-1{alpha} but does not increase mitochondrial gene expression and function.

Kleiner S, Nguyen-Tran V, Baré O, Huang X, Spiegelman B, Wu Z.

J Biol Chem. 2009 Jul 10;284(28):18624-33. doi: 10.1074/jbc.M109.008797. Epub 2009 May 12.

15.

(3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(methyl(1-methyl-1h-1,2,4-triazol-5-yl)amino)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoic acid (BMS-644950): a rationally designed orally efficacious 3-hydroxy-3-methylglutaryl coenzyme-a reductase inhibitor with reduced myotoxicity potential.

Ahmad S, Madsen CS, Stein PD, Janovitz E, Huang C, Ngu K, Bisaha S, Kennedy LJ, Chen BC, Zhao R, Sitkoff D, Monshizadegan H, Yin X, Ryan CS, Zhang R, Giancarli M, Bird E, Chang M, Chen X, Setters R, Search D, Zhuang S, Nguyen-Tran V, Cuff CA, Harrity T, Darienzo CJ, Li T, Reeves RA, Blanar MA, Barrish JC, Zahler R, Robl JA.

J Med Chem. 2008 May 8;51(9):2722-33. doi: 10.1021/jm800001n. Epub 2008 Apr 15.

PMID:
18412317
16.

The Guinea pig as a preclinical model for demonstrating the efficacy and safety of statins.

Madsen CS, Janovitz E, Zhang R, Nguyen-Tran V, Ryan CS, Yin X, Monshizadegan H, Chang M, D'Arienzo C, Scheer S, Setters R, Search D, Chen X, Zhuang S, Kunselman L, Peters A, Harrity T, Apedo A, Huang C, Cuff CA, Kowala MC, Blanar MA, Sun CQ, Robl JA, Stein PD.

J Pharmacol Exp Ther. 2008 Feb;324(2):576-86. Epub 2007 Nov 6.

PMID:
17986646
17.

A defect in the Kv channel-interacting protein 2 (KChIP2) gene leads to a complete loss of I(to) and confers susceptibility to ventricular tachycardia.

Kuo HC, Cheng CF, Clark RB, Lin JJ, Lin JL, Hoshijima M, Nguyêñ-Trân VT, Gu Y, Ikeda Y, Chu PH, Ross J, Giles WR, Chien KR.

Cell. 2001 Dec 14;107(6):801-13.

18.

A novel genetic pathway for sudden cardiac death via defects in the transition between ventricular and conduction system cell lineages.

Nguyên-Trân VT, Kubalak SW, Minamisawa S, Fiset C, Wollert KC, Brown AB, Ruiz-Lozano P, Barrere-Lemaire S, Kondo R, Norman LW, Gourdie RG, Rahme MM, Feld GK, Clark RB, Giles WR, Chien KR.

Cell. 2000 Sep 1;102(5):671-82.

Supplemental Content

Loading ...
Support Center